ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 556

Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims

Robin K. Dore1, Jenya Antonova2 and Jerrold Hill3, 1Univ of California, Los Angeles, CA, 2Gilead Sciences, Foster City, CA, 3Health Economics Outcomes Research, Real World Evidence, IQVIA, Plymouth Meeting, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: DMARDs and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The ACR treat-to-target approach for rheumatoid arthritis (RA) recommends regular assessments of disease activity and adjustment of medication regimen until efficacy goals are met. Given recent advances in pharmacologic therapy, this study assessed recent treatment patterns in RA patients (pts) who had newly initiated a DMARD.

Methods:

Adult pts with ≥2 claims for RA, initiating first DMARD between 1/2012–9/2016 (index date; ID) were identified in fully-adjudicated commercial medical and pharmacy health insurance claims, including self-insured, full-risk, and Medicare policies for approximately 40 million lives annually. Those with 12-months continuous enrollment pre- and post-ID and without DMARD claims 12 months pre-ID were selected. Initial utilization of conventional synthetic DMARDs (csDMARDs), TNF inhibitors (TNFi), anti-IL6 pathway antibodies, other biologic DMARDs (bDMARDs), and JAK inhibitors (JAKi), as monotherapy and in combination with csDMARDs, was summarized with descriptive statistics.  Median therapy duration was assessed with Kaplan-Meier method.  End of treatment was defined as drug discontinuation, switch to a new therapy, or addition of another DMARD.

Results:

Among 26,808 identified pts (74.2% female; mean age 51.9±11.0 yrs), 97.7% of pts initiated monotherapy and 2.3% started combination therapies. The most commonly-prescribed monotherapies were csDMARD (91.3%) and TNFi (6.6%). The most commonly-prescribed treatments in combination with csDMARDs included TNFi (88.0%) and other bDMARDs (7.3%). The median duration of csDMARD monotherapy was 230 days. The median treatment duration (combination vs monotherapy) was: 225 vs. 206 days (TNFi), 227 vs. 203 days (anti-IL6), 198 vs. 182 days (other bDMARDs), and 347 vs. 301 days (JAKi). JAKi treatment had the longest therapy duration when combined with csDMARDs (347 days), and other therapies lasted for a median of 182-230 days. As monotherapy, JAKi duration was 301 days, and other therapies lasted for a median of 198-227 days.

Conclusion:

Real-world data from US longitudinal healthcare claims showed that in RA pts newly initiating DMARDs, the median duration of therapy was less than a year, suggesting a need for a treatment with improved response durability. Duration of JAKi therapy was longer than median duration of other therapies. Further research is needed to determine the reasons for the longer persistence of JAKi therapy and why persistence is low with RA therapies overall.

 

Therapy initiated by DMARD naïve patients

N

% within monotherapy and combination therapy subgroups

Median length of therapy (days)1

% of subjects still on index therapy at day 360

Mean Age (SD)

Female

(N, %)

Mean CCI (SD)

Monotherapy

26182

 

227

38.3%

51.9 (11.0)

19429 (74.2)

1.3(1.1)

initiating csDMARD

23852

91.1%

230

38.6%

52.0 (10.9)

17730 (74.3)

1.3(1.1)

initiating TNFi

1739

6.6%

205

35.8%

50.6 (12.2)

1237 (71.1)

1.5(1.0)

initiating anti-IL6

99

0.4%

196

30.3%

54.5 (11.0)

75 (75.8)

1.5(1.0)

initiating other bDMARDs

398

1.5%

182

32.7%

53.2 (11.8)

312 (78.4)

1.6(1.2)

initiating JAKi

94

0.4%

301

46.8%

52.2 (9.3)

75 (79.8)

1.7(1.1)

 

 

100.0%

 

 

 

 

 

Combination therapy

626

 

224.5

37.1%

51.1 (11.0)

460 (73.5)

1.3 (1.0)

initiating csDMARD in combination with TNFi

551

88.0%

225

37.0%

51.2 (10.9)

401 (72.8)

1.3 (0.9)

initiating csDMARD in combination with anti-IL6

16

2.6%

227

43.8%

48.2 (14.7)

15 (93.8)

1.1(0.9)

initiating csDMARD in combination with other bDMARDs 

46

7.3%

198

32.6%

49.2 (11.5)

37 (80.4)

1.5(1.5)

initiating csDMARD in combination with JAKi

13

2.1%

347

46.2%

54.7 (8.8)

7 (53.9)

1.7 (1.0)

 

 

100.0%

 

 

 

 

 

Total monotherapy + combination therapy2

26808

 

 

 

51.9 (11.0)

19889 (74.2)

1.3(1.1)

1 Median days were derived from Kaplan-Meier analysis. LOT = length on therapy. Median days on 1st LOT were longer for patients on combination than on monotherapy (p<0.0001).

2 One patient initiating csDMARD in combination with other biologic DMARDs and TNFi, two patients initiating other biologic DMARDs in combination with TNFi, and two patients initiating TNFi in combination with JAKi were removed from the analysis due to insufficient sample size to form cohorts.

 


Disclosure: R. K. Dore, None; J. Antonova, Gilead Sciences, 3; J. Hill, Gilead Sciences Inc., 5.

To cite this abstract in AMA style:

Dore RK, Antonova J, Hill J. Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/treatment-initiation-and-duration-in-dmard-naive-rheumatoid-arthritis-patients-analysis-of-us-health-plan-claims/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-initiation-and-duration-in-dmard-naive-rheumatoid-arthritis-patients-analysis-of-us-health-plan-claims/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology